Neurogene Inc. 8-K

What Happened
Neurogene Inc. (NGNE) filed a Form 8-K on January 12, 2026 (Item 7.01, Regulation FD Disclosure) announcing that it issued a press release with recent corporate updates and a list of anticipated milestones for the coming year. On the same date the company posted an updated corporate presentation on its website. The press release is included as Exhibit 99.1 and the corporate presentation is furnished as Exhibit 99.2 to the 8-K. The filing is signed by Christine Mikail, President and Chief Financial Officer, dated January 12, 2026.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 7.01).
• Press release attached as Exhibit 99.1; corporate presentation furnished as Exhibit 99.2.
• Updated corporate presentation was posted publicly on the company website the same day.
• No financial results, earnings, management changes, mergers or acquisitions were reported in this filing.

Why It Matters
This 8-K is a Regulation FD disclosure: Neurogene is making material corporate updates and its near‑term milestones available publicly so all investors can access the same information at the same time. Investors should review the attached press release and presentation for any specific operational, clinical, regulatory, or timeline details that could affect the stock—particularly milestone timing that may influence future announcements. Because no earnings or executive changes were reported here, this filing is primarily informational; check the exhibits and future filings for any concrete financial or clinical results.